Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 13 systematic review(s)/meta-analysis(es). ^[1-13]
• Tezepelumab significantly reduced annualized asthma exacerbations, with an odds ratio (OR) of 0.67 (95% confidence interval (CI): [0.57, -0.80], P < .00001), and showed a relative risk (RR) of 0.63 (95% CI: [0.46, 0.86]) compared to placebo. Additionally, it consistently reduced airway hyperresponsiveness (AHR) in 3 studies.
• Tezepelumab improved lung function, with a standardized mean difference (SMD) of 0.28 (95% CI: [0.11, 0.45], P = .001) for forced expiratory volume in 1 second (FEV₁), and a mean improvement in FEV₁ of 0.24 L (95% CI: [0.16, 0.32]) compared to placebo.
• Tezepelumab demonstrated significant improvements in asthma control, as evidenced by reductions in asthma control questionnaire scores (Asthma Control Questionnaire (ACQ)-6 (standard mean difference (SMD) = -0.29, 95% CI = [-0.39, -0.20], P < .00001)) (SMD = -0.29, 95% CI: [-0.39, -0.20], P < .00001), and improved health-related quality of life for patients with asthma.
• Biomarker reductions were observed with tezepelumab, including a decrease in fractional exhaled nitric oxide (FeNO) (mean difference (MD) = -10 ppb, 95% CI: [-15.81, -4.18], P = 0.0008) and blood eosinophil count (MD = -139.38 cells/mcL, 95% CI: [-150.37, -128.39], P < 0.00001).
• Adverse Events: Tezepelumab was associated with common mild adverse events, such as nasopharyngitis, headache, and bronchitis. However, there was a significant reduction in serious adverse events compared to placebo, and patients treated with tezepelumab did not experience a higher incidence of adverse drug reactions compared to placebo.
• Antidrug Antibodies (ADAs): The incidence of antidrug antibodies with tezepelumab was low at 1.12%, compared to higher rates observed with other biologics, such as benralizumab (8.35%). No significant neutralizing antibodies were reported, indicating a favorable immunogenicity profile for tezepelumab.
• Comparison with Other Biologics: Tezepelumab demonstrated a better safety profile with fewer serious adverse events compared to other biologics like omalizumab, reslizumab, and mepolizumab, making it a favorable option in terms of safety for asthma management.
• Tezepelumab demonstrated consistent efficacy in reducing asthma exacerbation rates across both T2-high and T2-low inflammation subgroups, with reductions in annualized asthma exacerbation rates observed across all baseline blood eosinophil count (BEC) categories, including patients with lower BEC (< 300 cells/µL), where other biologics showed reduced efficacy.